[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100338040":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":61,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":31,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":31,"enrollmentInfo":77,"targetDuration":31,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":45,"whyStopped":31,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tofacitinib","EXPERIMENTAL","Patient will receive two days treatment with tofacitinib prior to the surgery.",[13],"Drug: Tofacitinib 10 MG [Xeljanz]",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Patient will receive two days treatment with placebo prior to the surgery.",[19],"Drug: Placebo to match Tofacitinib",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tofacitinib 10 MG [Xeljanz]","administered twice daily for two days",[9],[27],"XELJANZ",{"type":22,"name":29,"description":24,"armGroupLabels":30,"otherNames":31},"Placebo to match Tofacitinib",[15],null,[33],{"name":34,"affiliation":5,"role":35},"Joseph Shrager, MD","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":31,"email":41},"Cheyenne A Clinical Research Coordinator, B.S, M.S","CONTACT","3107201689","csadeghi@stanford.edu",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Stanford University Medical Center","RECRUITING","Stanford","California","94305","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-122.16608,37.42411,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":31,"email":41},"Study Team","650-721-6561",{"type":35,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Joseph B. Shrager, MD","Professor",[65],{"name":66,"class":67},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100338040","phase-2-janus-kinase-inhibition-to-prevent-ventilator-induced-diaphragm-dysfunction-100338040",false,"NCT03681275","Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction","A Clinical Trial of JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction","Inclusion Criteria:\n\n* Patients undergoing esophagectomy\n\nExclusion Criteria:\n\n* Patients with more than mild pulmonary dysfunction\n* Patients with any neuromuscular disease that might compromise diaphragm function\n* Patients with abnormal liver or kidney function\n* Patients taking any immunosuppressant medication (including prednisone) or antifungal medications\n* History of tuberculosis\n* Weight loss of \\>5% of body weight over previous 6 months\n* Pregnancy","ALL","18 Years",{"count":78,"type":79},70,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.",[85],"Diaphragm Injury",[87],"Ventilator-induced Diaphragm Dysfunction","2024-11-21",{"date":90,"type":91},"2024-11-25","ACTUAL",{"date":93,"type":91},"2019-09-03",{"date":95,"type":79},"2026-11-30",{"name":5,"class":6},1]